Jean-Paul Kress

Independent director
Jean-Paul Kress - Independent Director Member at the Board of Directors of Sanofi, Member of the Strategy Committee and Member of the Scientific CommitteeJean-Paul Kress, Independent director

At a Glance

Date of birth

August 01, 1965

Nationality

French

First elected or appointed

January 2025

Term expires

General Meeting 2026

Education and Business Experience

Jean-Paul Kress, M.D., served as the CEO of MorphoSys from 2019 until it was acquired by Novartis in 2024.

Prior to this, Jean-Paul Kress was the CEO of Syntimmune, where he sharpened the company’s focus on late-stage clinical development in auto-immune diseases until the company’s acquisition by Alexion. He has also held several senior leadership roles at other pharmaceutical companies in the US and in Europe. Jean-Paul Kress served as Chairman of the Board of Directors at ERYTECH Pharma and was a member of Sarepta Therapeutics’ Board of Directors.

He received his M.D. from Faculté Necker-Enfants Malades in Paris and Master of Sciences in molecular and cellular pharmacology from Ecole normale supérieure (Ulm) in Paris.

Contact information

46, avenue de la Grande Armée - 75017 Paris (France)

Jean-Paul Kress on LinkedIn

Directorships & Appointments

Inside the Sanofi Group

Independent director

Member of the Strategy Committee

Member of the Scientific Committee

Meet the Sanofi Board of Directors

Frédéric Oudéa - Chairman of the Board of Directors

Frédéric Oudéa

Chairman of the Board of Directors

See more